Glioblastoma is an aggressive brain cancer for which there is no known cure. The current treatment options for glioblastoma are invasive surgery and chemotherapy and the 5-year survival rate for patients with glioblastoma is 18%. Diagnosis and treatment of glioblastoma could be greatly improved if the disease could be detected earlier.
Researchers Sarah Hernandez and Tanja Dominko from Worcester Polytechnic Institute have identified a new biomarker that can preferentially kill glioblastoma cells within six days. The biomarker also predicts survival of pre-cancerous cells, cells that are likely to develop into cancer.
This novel technology is available for licensing and could be used to develop new diagnostic tests and therapeutics for early-stage cancer.